Consideration of ROR1 v1 expression in MCL, DLBCL and FL is a crucial topic for an accurate biomarker trial patient selection strategy to assure efficacy of new therapeutic modalities targeting ROR1 such as ADC, TCE, or CAR-T, as their mode-of-actions relies on the presence of membrane tumour target [1, 10]. The gene discussed is ROR1; the disease is diffuse large B-cell lymphoma.